ngµç×ÓÓÎÏ·

05

¿ÆÑÐÏ£Íû

ÖÐɽÑÛ¿ÆÖÐÐijÙçâ/ºúÓѽðÍŶӷ¢Ã÷Vogt-СÁøÔ­Ìï×ÛºÏÕ÷»¼ÕßеÄÖ²¡ÐÔµ¥ºËϸ°ûÑÇȺ¼°·Ö×ÓÕï¶Ï±ê¼ÇÎï

¸å¼þȪԴ£º£ºÖÐɽÑÛ¿ÆÖÐÐÄ ÔĶÁÁ¿£º£º

¿ËÈÕ£¬£¬£¬ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐijÙçâ×÷ΪͨѶ×÷Õß¡¢¡¢¡¢ºúÓѽð×÷ΪµÚÒ»×÷ÕßÏàÖú¿ªÕ¹Ñо¿£¬£¬£¬ÔÚ×ÔÉíÃâÒßÐÔÆÏÌÑĤÑ׵ķ¢²¡»úÖÆºÍ¾«×¼ÕïÁÆÁìÓò·¢Ã÷Vogt-СÁøÔ­Ìï×ÛºÏÕ÷»¼ÕßеÄÖ²¡ÐÔµ¥ºËϸ°ûÑÇȺ¼°·Ö×ÓÕï¶Ï±ê¼ÇÎï¡£¡£¸ÃÑо¿ÂÛÎÄ¡°Genetic landscape and autoimmunity of monocytes in developing Vogt-Koyanagi-Harada disease¡±ÒÔresearch articleÐÎʽÔÚÏß½ÒÏþÓÚ¹ú¼ÊÖøÃûÆÚ¿¯PNAS£¨×îÐÂÓ°ÏìÒò×Ó£º£º9.412£¬£¬£¬ÎåÄêÓ°ÏìÒò×Ó£º£º10.62£©¡£¡£

Vogt-СÁøÔ­Ìï×ÛºÏÕ÷£¨Vogt-Koyanagi-Harada syndrome, VKH£©ÊÇÑÇÖÞÈË×î³£¼ûµÄ×ÔÉíÃâÒßÐÔÆÏÌÑĤÑ×ÀàÐÍ£¬£¬£¬ºÃ·¢ÓÚÇà׳Äê¡¢¡¢¡¢Æð²¡¼±¾ç¡¢¡¢¡¢Ë«ÑÛÊÓÁ¦Ëðº¦ÑÏÖØ£¬£¬£¬°éÓÐÉñ¾­ÏµÍ³¡¢¡¢¡¢ÌýÁ¦ÏµÍ³¡¢¡¢¡¢Æ¤·ôë·¢µÈ¶àÆ÷¹ÙµÄË𺦡£¡£ÓÉÓÚ¼²²¡Öظ´±¬·¢£¬£¬£¬³£Ôì³É»¼ÕßË«ÑÛÑÏÖØµÄ²»¿ÉÄæÊÓÁ¦Ëðʧ¡¢¡¢¡¢ÉõÖÁäĿ¡£¡£¸Ã¼²²¡ÔçÆÚÕï¶ÏÖÎÁÆÐ§¹ûºÃ£¬£¬£¬µ«ÒòÁÙ´²ÌåÏÖÖØ´óÇÒȱ·¦ÌØÒìÐÔµÄÕï¶Ï±ê¼ÇÎ£¬£¬¼«Ò×ÎóÕï¶øÑÓÎó×î¼ÑÖÎÁÆÊ±»ú¡¢¡¢¡¢Ôì³ÉÓÀÊÀµÄÊÓÁ¦Ë𺦡£¡£²¢ÇÒ£¬£¬£¬VKH×ÛºÏÕ÷µÄ·¢²¡»úÖÆÏÖÔÚÉв»Ã÷È·£¬£¬£¬È±·¦Ã÷È·µÄÖÎÁưеãºÍÌØÒìÐÔÖÎÁÆÒ©Îï¡£¡£Òò´Ë£¬£¬£¬ÉîÈëÑо¿VKH×ÛºÏÕ÷µÄ·¢²¡»úÖÆ¡¢¡¢¡¢½¨Éè·Ö×ÓÕï¶Ï±ê¼ÇÎï¡¢¡¢¡¢È·¶¨ÖÎÁưеã¶Ô´ËÀ໼ÕßµÄÖÎÁƺÜÊÇÒªº¦£¬£¬£¬¸ÃÑо¿Î§ÈÆVKH×ÛºÏÕ÷µÄ¾«×¼ÕïÖÎÉîÈëÕö¿ª¡£¡£

Ñо¿ÕßÃÇÊ״ζÔVKH×ÛºÏÕ÷»¼Õߵĵ¥ºËϸ°û¾ÙÐÐϸÄåµÄµ¥ºËϸ°û·ÖȺ£¬£¬£¬ÕâÒ²ÊÇÊׯª¹ØÓÚÈËÀà×ÔÉíÃâÒßÐÔ¼²²¡»¼ÕßµÄеÄϸ°û·ÖȺ±¨µÀ¡£¡£ËûÃÇ·¢Ã÷ÁËÁ½ÈºÎ´±¨µÀ¹ýµÄе¥ºËϸ°ûÑÇȺ£¬£¬£¬²¢½«ÆäÃüÃûΪpro-inflammatory-ºÍHLA-µ¥ºËϸ°ûÑÇȺ£¬£¬£¬²¢È·Ö¤pro-inflammatoryµ¥ºËϸ°ûÑÇȺ¾ßÓÐÖ÷ÒªµÄÖ²¡×÷Óᣡ£ËûÃÇ»¹·¢Ã÷ÁËpro-inflammatoryÑÇÈºÌØÒìÐÔ±í´ïµÄ·ºËØÑùÂѰ×ISG15ÊǶÔVKH×ÛºÏÕ÷¾ßÓÐÕï¶Ï¼ÛÖµµÄÌØÕ÷ÐÔ·Ö×Ó±ê¼ÇÎ£¬£¬ÔÚVKH»î¶¯ÆÚ»¼ÕßÖÐÌØÒìÐÔ±í´ï£»£»£»²¢ÇÒÏà½ÏÓÚOCT¡¢¡¢¡¢FFAµÈÁÙ´²¼ì²éÒªÁ죬£¬£¬ISG15¿ÉÒÔ¸ü¾«×¼µØÔ¤²âÖÎÁƺóÌåÄÚµÄÃâÒßÑ×Ö¢»î¶¯³Ì¶È£¬£¬£¬¾«×¼Ö¸µ¼ÖÎÁÆ·½°¸µÄÑ¡Ôñ£¬£¬£¬×èÖ¹ÁË´ó¼ÁÁ¿¼¤Ëصĺã¾ÃʹÓᣡ£ISG15µÄ·¢Ã÷Ìî²¹ÁË´ËÀ༲²¡ÎÞÌØÒìÐÔÕï¶Ï±ê¼ÇÎïµÄ¿Õȱ£¬£¬£¬×èÖ¹ÁËÖڶ໼ÕßÒòÎóÕï¶ø´øÀ´µÄÖÕÉíÊÓÁ¦Ë𺦡£¡£°ÐÏòpro-inflammatoryµ¥ºËϸ°ûÑÇȺµÄÖÎÁÆ£¬£¬£¬ÎªÆÏÌÑĤÑ×µÄÖÎÁÆÕÒµ½ÐÂµÄÆ«Ïò¡£¡£

¹Å°åÉϵ¥ºËϸ°û·ÖΪ¾­µä·¶¡¢¡¢¡¢·Ç¾­µä·¶ºÍÖÐÐÄÐÍÈýÀà¡£¡£Ñо¿ÕßÃÇÊ״ν«¶ÔÈËÀ൥ϸ°û¾ÙÐÐϸÄå·ÖȺ½«È˵¥ºËϸ°ûƾ֤ÆäÌØÒìÐÔ·Ö×Ó±ê¼ÇÎï·ÖΪ6¸öϸ°ûÑÇȺ£¬£¬£¬²¢Æ¾Ö¤Æä¹¦Ð§ÃüÃûΪS100A12¡¢¡¢¡¢HLA¡¢¡¢¡¢CD16¡¢¡¢¡¢Pro-inflammatory¡¢¡¢¡¢Megakaryocyte-likeºÍNK-likeµ¥ºËϸ°ûÑÇȺ£¬£¬£¬²¢·¢Ã÷ÁËÁ½ÈºÎ´±¨µÀ¹ýµÄÑÇȺ¡£¡£¸ÃÑо¿Åú×¢S100A12 MonoÊǵ¥ºËϸ°ûÖÐ×î´óµÄÑÇȺ£»£»£»HLA MonoÖ÷Òª±í´ïÖÖÖÖÈËÀà°×ϸ°û¿¹Ô­£¨human leukocyte antigen, HLA£©£»£»£»CD16 Mono×Åʵ¶ÔÓ¦µÄÊǷǾ­µä·¶µ¥ºËϸ°û£¬£¬£¬ÏÔÖø±í´ïFCGR3A/CD16£¬£¬£¬Pro-inflammatory MonoÏÔÖø±í´ï°×ϸ°û½éËØ£¨IL-1B£©,Ç÷»¯Òò×Ó£¨CCL3¡¢¡¢¡¢CCL4£©µÈÓëÑ×Ö¢Ç×½üÏà¹ØµÄ·Ö×Ó£»£»£»Megakaryocyte-like MonoµÄ·Ö×ÓmarkerÓë¾ÞºËϸ°ûÊ®·ÖÀàËÆ£¨PPBP¡¢¡¢¡¢PF4£©£¬£¬£¬µ«ÓÖͬʱ¸ß±í´ïCD14µÈµ¥ºËϸ°ûÌØÕ÷ÐÔ·Ö×Ómarker£¬£¬£¬Òò´Ë½«Æä½ç˵Ϊ¾ÞºËϸ°ûÑùµ¥ºËϸ°û£»£»£»NK-like MonoÊÇÒ»ÀàºÜСµÄµ¥ºËϸ°ûÑÇȺ£¬£¬£¬ÊýÄ¿×îÉÙ£¬£¬£¬Ö÷Òª±í´ïÓëNKϸ°ûÀàËÆµÄ·Ö×Ó±ê¼ÇÎï¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ1. ʹÓõ¥Ï¸°ûRNA²âÐòÊÖÒÕÆÊÎöVKH²¡È˺ÍÕý·²È˵ÄÍâÖÜѪϸ°ûת¼ͼÆ×

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ2. »ùÓÚµ¥Ï¸°ûת¼ͼÆ×ÆÊÎöºÍÅжÏÍâÖÜѪµ¥ºËϸ°ûÑÇȺ

½ÓÏÂÀ´Ñо¿ÕßÃǶԸ÷µ¥ºËϸ°ûÑÇȺ¾ÙÐÐÁ˹¦Ð§ÆÊÎö£¬£¬£¬·¢Ã÷Pro-inflammatory ÑÇȺÓëVKH¼²²¡µÄÑÛÄÚÑ×Ö¢Ïà¹Ø£¬£¬£¬¾ßÓÐÖ²¡ÐÔ¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ3. VKH²¡ÈËÖе¥ºËϸ°ûÌØ¶¨ÑÇȺµÄ»ùÒò±í´ï±¬·¢ÏÔÖø×ª±ä

Ñо¿ÕßÃǶÔPro-inflammatory Mono×öÁ˽øÒ»²½ÉîÈëµÄÑо¿£¬£¬£¬·¢Ã÷Á˸ÃÑÇȺ¸ß±í´ïµÄ·ºËØÑùÂѰ×ISG15¿ÉÒÔ×÷Ϊ¼±ÐÔÆÚVKH×ÛºÏÕ÷µÄÔçÆÚ·Ö×ÓÕï¶Ï±ê¼ÇÎ£¬£¬±ÈFFAºÍOCT¸ü׼ȷµØÕï¶Ï»¼ÕßÌåÄÚµÄÑ×Ö¢»î¶¯×´Ì¬ºÍ¶ÔÒ©Îï·´Ó³£¬£¬£¬´Ó¶øÎª¼²²¡µÄÔçÆÚÕï¶ÏºÍ¾«×¼ÖÎÁÆÌṩȷÇеÄÒªÁì¡£¡£

Ê×Ò³|ngµç×ÓÓÎÏ·Öйú¼¯ÍŹٷ½ÍøÕ¾

ͼ4. ISG15¹ØÓÚVKH¼²²¡»î¶¯×´Ì¬ÓÐÏÔ×ŵÄÌáÐÑ×÷ÓÃ

ngµç×ÓÓÎÏ·ÖÐɽÑÛ¿ÆÖÐÐÄΪµÚÒ»µ¥Î»£¬£¬£¬³Ùçâ½ÌÊÚΪ±¾ÎÄͨѶ×÷Õߣ¬£¬£¬ºúÓѽð½ÌÊÚ¡¢¡¢¡¢ºúÒëÐIJ©Ê¿ºÍФÓñ»ªÎª±¾ÎĵIJ¢ÁеÚÒ»×÷Õß¡£¡£¸ÃÑо¿Í¬Ê±»ñµÃÁ˹ú¼ÒÖØµãÑз¢ÍýÏë¡¢¡¢¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðºÍ¹ãÖÝÊпƼ¼ÏîÄ¿µÄÖ§³Ö¡£¡£

ÂÛÎÄÁ´½Ó£º£ºhttps://www.pnas.org/content/early/2020/09/25/2002476117

¡¾ÍøÕ¾µØÍ¼¡¿